Fern M. Anari, MD

Dr. Fern Anari
​​
This physician is not currently rated. Why?

Why is this doctor not rated?

Close

To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings
Request an Appointment

Clinical Locations

Assistant Professor, Department of Hematology/Oncology

Treatment Focus

Chemotherapy, targeted therapy, immunotherapy, hormone therapy, clinical trials for genitourinary malignancies

Key Awards

2023 top doctors
Medical Oncology

Treatment Philosophy

I am a medical oncologist specializing in cancers of the genitourinary tract. A new cancer diagnosis can be both overwhelming and life-changing for patients and their loved ones. As a medical oncologist, it is my privilege to help patients navigate this new world by not only helping them understand their diagnosis and treatment options, but also by providing support and guidance along the way. Every patient has a unique experience, so it is important for me to build a relationship with each person I meet so I can best understand his or her values in order to treat each person as a whole. My patients are my number one priority. It is my mission to make sure any and all questions are answered, and that patients and their families feel comfortable with every decision made throughout their journey. 

At Fox Chase Cancer Center, I am lucky to work as part of a multidisciplinary team alongside other medical oncologists, urologists, radiation oncologists and other cancer specialists, which allows me to provide the highest quality of care in a personalized manner tailored to each patient. Being a part of Fox Chase allows me to offer patients both standard-of-care treatments and new, cutting edge treatment options through clinical trial participation. The field of medical oncology is rapidly evolving and Fox Chase is on the forefront of these exciting changes.     

Educational Background

  • Fellowship, Hematology/Medical Oncology, Fox Chase Cancer Center/Temple University Hospital, Philadelphia, PA
  • Residency, Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA
  • MD, Rutgers/Robert Wood Johnson Medical School, New Brunswick, NJ

Certifications

  • American Board of Internal Medicine, Medical Oncology, 2019
  • American Board of Internal Medicine, Hematology, 2019
  • American Board of Internal Medicine, Internal Medicine, 2016

Memberships

  • American Society of Clinical Oncology
  • American Society of Hematology
  • Alpha Omega Alpha Honor Medical Society

Honors & Awards

  • American Medical Women's Association Glasgow-Rubin Citation for Academic Achievement, 2013
  • Angelo P. Angelides Award for Academic Excellence in Medicine, 2013

 

Selected Publications

  • Winer A, Ghatalia P, Bubes N, Anari F, Varshavsky A, Kasireddy V, Liu Y, El-Deiry WS. Dual checkpoint inhibition with ipilimumab plus nivolumab after progression on sequential PD-1/PDL-1 inhibitors pembrolizumab and atezolizumab in a patient with Lynch Syndrome, metastatic colon and localized urothelial cancer. The Oncologist.
  • Ghatalia P, Smith CH, Winer A, Gou J, Kiedrowski LA, Saltzberg PD, Bubes N, Anari F, Kasireddy V, Varshavsky A, Liu Y, Ross E, El-Deiry WS. Clinical use of liquid biopsies to detect actionable driver mutations, guide treatment decisions and monitor disease burden during treatment of 33 metastatic colorectal cancer patients at Fox Chase Cancer Center GI Oncology subspecialty clinic. Frontiers in Oncology. 2019 Jan, 8(1-8).    
  • Anari F, Dotan E. Management of Older Adults with Colorectal Cancer. Hospital Physician Hematology/Oncology Board Review Manual. 2018,13(4):7-22. 
  • Anari F, Ramamurthy C, Zibelman M. Impact of Tumor Microenvironment Composition on Therapeutic Responses and Clinical Outcomes in cancer. Future Oncology. 2018 Jun;14(14):1409-1421.
  • Anari F, O’Neill J, Choi W, Chen D, Haseebuddin M, Kutikov A, Dulaimi E, Alpaugh RK, Devarajan K, Greenberg R, Bilusic M, Wong YN, Viterbo R, Hoffman-Censits JH, Lallas C, Trabulsi E, Smaldone M, Geynisman D, Zibelman M, Lin J, Kelly WK, Uzzo R, McConkey D, Plimack ER. Neoadjuvant Dose-Dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial. European Urology Oncology. 2018 May;1(1):54-60.

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...
​​